Publications by authors named "Denis Maillet"

Claim this Profile
C
Chemotherapy use in triplet approach for metastatic hormone-sensitive prostate cancer: French practice survey and expert opinion.
Delphine Borchiellini, Gwenaelle Gravis, Emmanuel Gross, Jean-Michel Hannoun-Levi, Jean-François Berdah, Denis Maillet

Fr J Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: Rationale, Mechanisms, and Clinical Applications.
Stéphane Oudard, Marc-Olivier Timsit, Denis Maillet, Guillaume Mouillet, Luca Campedel

Eur Urol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.
Andrew J Armstrong, Fred Saad, Mototsugu Oya, Karina Vianna, Mustafa Özgüroğlu, Denis Maillet

Eur Urol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study.
Thibaut Reverdy, Floriane Izarn, Benoit Allignet, Guilhem Roubaud, Nyere Gibson, Denis Maillet

Clin Genitourin Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting recurrence and progression in NMIBC: A multi-event and temporal analysis approach.
Hugo Brouzes, Said Ourfali, Hakim Fassi-Fehri, Melanie Benoit-Janin, Nadia Abid, Denis Maillet

Fr J Urol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Pierre Yves Meunier, Karfala Maiga, Denis Maillet, Thomas Bochaton, Benoît De la Fournière

Sante Publique· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving Practices in Immune-Related Adverse Event Management: Insights From the IMMUCARE Multidisciplinary Board.
Romain Varnier, Clara Fontaine-Delaruelle, Nathalie Freymond, Aurore Essongue, Anissa Bouali, Denis Maillet

JCO Oncol Pract· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cutaneous Anguillulosis During Immunotherapy for Metastatic Renal Cell Carcinoma.
Pierre Cornillon, Marie Beguinot, Denis Maillet, Wafa Bouleftour, Yanis Bouqallaba

Medicina (Kaunas)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations].
Stéphane Oudard, Marc-Olivier Timsit, Denis Maillet, Guillaume Mouillet, Luca Campedel

Bull Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of immune checkpoint inhibitors in renal cell carcinoma venous tumour thrombus shrinkage (UroCCR 128).
Fabien Moinard-Butot, Jonathan Thouvenin, Pierre Bigot, Nieves Martinez-Chanza, Victor Gaillard, Denis Maillet

World J Urol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.
Fred Saad, Andrew J Armstrong, Mototsugu Oya, Karina Vianna, Mustafa Özgüroğlu, Denis Maillet

Eur Urol Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of radiotherapy on bone metastases from prostate adenocarcinoma: What is the future for the combination with radiotherapy/immunotherapy?
Pierre Cornillon, Wafa Bouleftour, Thomas Reynaud, Gregoire Pigne, Denis Maillet

Tumori· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Major drug-drug interaction between sirolimus and apalutamide in a liver transplant recipient.
Jérôme Dumortier, Marc Colombel, Denis Maillet

Transpl Immunol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study.
Antonio Farina, Macarena Villagrán-García, Anthony Fourier, Anne-Laurie Pinto, Fatima Chorfa, Denis Maillet

Lancet Reg Health Eur· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidisciplinary real-world management of metastatic castration-sensitive prostate cancer: A French national study (PROFILE study).
Carole Helissey, Denis Maillet, Bérengère Narciso, Jean-François Berdah, Idir Ouzaid

Fr J Urol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial.
Jérôme Alexandre, Stephane Oudard, Lisa Golmard, Luca Campedel, Mourad Mseddi, Denis Maillet

Clin Pharmacokinet· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA.
Aurore Carrot, Stéphane Oudard, Olivier Colomban, Karim Fizazi, Denis Maillet

JCO Clin Cancer Inform· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, Ignacio Duran, Simon J Crabb, Denis Maillet

Nat Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study.
Edwige Baudry, Natacha Naoun, Edouard Auclin, Carolina Saldana, Philippe Barthelemy, Denis Maillet

Eur J Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
Claire Masson, Jonathan Thouvenin, Philippe Boudier, Denis Maillet, Sabine Kuchler-Bopp

Cancers (Basel)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Romain Varnier, Alicja Puszkiel, Michel Tod, Sara Calattini, Lea Payen, Denis Maillet

Cancer Chemother Pharmacol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Alicja Puszkiel, Benoit You, Léa Payen, Jonathan Lopez, Jérôme Guitton, Denis Maillet

Cancer Chemother Pharmacol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients' Outcomes?
Jonathan Thouvenin, Claire Masson, Philippe Boudier, Denis Maillet, Sabine Kuchler-Bopp

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study.
Madeleine Maugeais, Julien Péron, Stéphane Dalle, Amélie Boespflug, Michaël Duruissaux, Denis Maillet

Biomedicines· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab.
Félix Pham, Samy Belkaid, Denis Maillet, Cyrille B Confavreux, Stéphane Dalle

Biomedicines· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis